Literature DB >> 28382329

Familial childhood-onset progressive cerebellar syndrome associated with the ATP1A3 mutation.

Fatima Jaffer1, Katherine Fawcett1, David Sims1, Andreas Heger1, Henry Houlden1, Michael G Hanna1, Helen Kingston1, Sanjay M Sisodiya1.   

Abstract

Entities:  

Year:  2017        PMID: 28382329      PMCID: PMC5367920          DOI: 10.1212/NXG.0000000000000145

Source DB:  PubMed          Journal:  Neurol Genet        ISSN: 2376-7839


× No keyword cloud information.
The allelic disorders rapid-onset dystonia-parkinsonism (RDP), alternating hemiplegia of childhood (AHC), and CAPOS/CAOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural deafness) are caused by ATP1A3 mutations.[1-3] Intermediate RDP-AHC phenotypes are emerging. Positional mutations 274, 583, 867, and 923 lead to both RDP and AHC, suggesting different pathomechanisms.[4,5] The E818K mutation underlies all reported cases of CAPOS/CAOS, including an AHC-CAPOS overlap syndrome.[6] We report a family with features of all 3 ATP1A3-spectrum disorders.

Case report.

The proband (II-3; figure, A) is 49 years old, born at 32 weeks of gestation with pre-eclampsia complicating pregnancy. Development was delayed, walking at 28 months with progressive gait ataxia, and speaking at 30 months. Hypertonia and choreoathetosis were present at this time. Aged 5 years, she developed fever-induced acute-onset generalized hypotonia and dysarthria. Motor weakness persisted for 8 months, requiring neurorehabilitation to reacquire independent ambulation. Aged 6 years, she developed limb incoordination and dysarthria, worsening during febrile illnesses. Childhood-onset painful limb spasms and stimulus-sensitive finger myoclonus were reported. At 30 years, she noted further worsening of dysarthria and ataxia. Examination at 49 years revealed short stature, low-set ears, scoliosis, and pes planus. She had marked cerebellar signs with dysarthria, dysmetria, square wave jerks, intention tremor, and gait ataxia and spasticity with preserved muscle strength, choreoathetosis, finger myoclonus, and cervical dystonia. Reflexes were absent and sensation intact. Fundoscopy and hearing were normal. MRI showed cerebellar atrophy.
Figure

Pedigree and genetics

(A) Family pedigree: no clinical information is available on the parents of the proband; Sanger sequencing confirmed the presence of c.2267G>A; p.Arg756His (indicated by *) in the ATP1A3 gene in all affected family members and was absent in unaffected family members, II-1 and III-3 (indicated by [-]). (B) Validation of mutation by Sanger sequencing. Chromatograms showing segregation of the variant with disease: present in affected family members II-3, III-2, and IV-1 and absent in II-1 and III-3. (C) Mutation map of the ATP1A3 gene. ATP1A3 mutation map showing all published mutations associated with rapid-onset dystonia-parkinsonism (RDP) (top panel), CAPOS/CAOS (top panel; highlighted in green), and alternating hemiplegia of childhood (AHC) (bottom panel). Mutations underlined indicate frequently reported variants associated with the disease; mutations in our patients are indicated in red; amino acid positions 274, 583, 923, and 801 highlighted in blue are mutated in both RDP and AHC; * indicates intronic splice-site variant c.2542 +1G>A.

Pedigree and genetics

(A) Family pedigree: no clinical information is available on the parents of the proband; Sanger sequencing confirmed the presence of c.2267G>A; p.Arg756His (indicated by *) in the ATP1A3 gene in all affected family members and was absent in unaffected family members, II-1 and III-3 (indicated by [-]). (B) Validation of mutation by Sanger sequencing. Chromatograms showing segregation of the variant with disease: present in affected family members II-3, III-2, and IV-1 and absent in II-1 and III-3. (C) Mutation map of the ATP1A3 gene. ATP1A3 mutation map showing all published mutations associated with rapid-onset dystonia-parkinsonism (RDP) (top panel), CAPOS/CAOS (top panel; highlighted in green), and alternating hemiplegia of childhood (AHC) (bottom panel). Mutations underlined indicate frequently reported variants associated with the disease; mutations in our patients are indicated in red; amino acid positions 274, 583, 923, and 801 highlighted in blue are mutated in both RDP and AHC; * indicates intronic splice-site variant c.2542 +1G>A. Individual III-2 was delivered at term and had delayed development, sitting at age 10 months, speaking at 18 months, and walking at 27 months with ataxia. At 30 months, she transiently lost the ability to walk, with upper limb ataxia, lasting 3 weeks after a febrile illness. She had another episode after Varicella zoster infection, with acute-onset generalized hypotonia, dysarthria, and dysphagia lasting for 1 month, followed by slow recovery. Examination at age 5.5 years showed persistent cerebellar signs with dysarthria, gait, and limb ataxia. She continues to have episodic cerebellar deterioration during intercurrent illness, with a recovery period of 1–2 days and complete return to baseline function. Examination at 20 years showed dysarthria, dysmetria, square wave jerks, gait ataxia, spasticity with normal muscle strength, global hyporeflexia with down-going plantar responses, and normal sensation. Athetoid movement of the hands, finger myoclonus, and scoliosis were present. There was no visual or hearing impairment. Brain MRI shows nonspecific mild periventricular white-matter changes and normal cerebellar volume. Individual IV-1 presented at age 8 months with generalized weakness during a febrile illness, taking 3 weeks to recover and be able to sit independently again. She started walking at age 17 months, and at 2 years, was ataxic and unable to walk independently. Vision and hearing were normal. Mutation analysis for spinocerebellar ataxias 1, 2, 3, 5, 7, and 17, dentatorubral-pallidoluysian atrophy, ferritin light chains, and common mitochondrial DNA mutations in the proband were negative, as were plasma acylcarnitine profile, lactate, ammonia, and amino acids. Whole-exome sequencing revealed a deleterious missense mutation, c.2267G>A; p.Arg756His (R756H), in ATP1A3, confirmed by Sanger sequencing and shown to segregate with the disease (figure, B).

Discussion.

Infantile-onset RDP with motor delay and initial fluctuations evolving into persistent dystonia and ataxia is reported with R756H mutations.[7] With the exception of IV-1, our patients presented with motor delay prior to paroxysmal motor symptoms, with a protracted recovery period, consistent with this picture. The development of a progressive cerebellar syndrome with superimposed fever-induced fluctuation is a key clinical feature in all three affected members of our family as is global hyporeflexia, suggesting some features also of CAPOS/CAOS syndrome, without visual or auditory involvement. Development of gait ataxia preceding episodic features broadens the phenotype away from CAPOS/CAOS and infantile-onset RDP. CAPOS are associated with pes cavus: recently, cases without are reported.[3] Our proband has flat feet, and she and her daughter have scoliosis, extending the musculoskeletal phenotype of ATP1A3-spectrum syndromes. The age at onset in this family fits with CAPOS/CAOS and AHC, and the development of pyramidal signs and an extrapyramidal disorder observed is more in keeping with nonparoxysmal AHC/RDP features. Overall, the phenotypic presentation has features of all three ATP1A3-spectrum disorders. The early-onset cerebellar ataxia prior to paroxysmal symptoms and extended musculoskeletal involvement is novel. Early MRI is unavailable: however, cerebellar atrophy in adulthood is observed in the proband, suggesting possible progression and development of fixed deficits observed in other neurologic channelopathies. Reporting unique ATP1A3-spectrum phenotypes facilitates genotype-phenotype correlation, although some phenotypic aspects may escape detection, directs functional studies and possible therapeutic targets. We propose that ATP1A3 mutation analysis is considered in patients with delayed motor development and childhood- or early-onset progressive cerebellar syndromes with superimposed acute motor fluctuations.
  7 in total

1.  Intermediate form between alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism.

Authors:  Masayuki Sasaki; Atsushi Ishii; Yoshiaki Saito; Shinichi Hirose
Journal:  Mov Disord       Date:  2013-09-30       Impact factor: 10.338

2.  The expanding clinical and genetic spectrum of ATP1A3-related disorders.

Authors:  Hendrik Rosewich; Andreas Ohlenbusch; Peter Huppke; Lars Schlotawa; Martina Baethmann; Inês Carrilho; Simona Fiori; Charles Marques Lourenço; Sarah Sawyer; Robert Steinfeld; Jutta Gärtner; Knut Brockmann
Journal:  Neurology       Date:  2014-02-12       Impact factor: 9.910

3.  Childhood-onset ATP1A3-related conditions: Report of two new cases of phenotypic spectrum.

Authors:  Francesco Nicita; Lorena Travaglini; Sandro Sabatini; Barbara Garavaglia; Celeste Panteghini; Massimiliano Valeriani; Enrico Bertini; Nardo Nardocci; Federico Vigevano; Alessandro Capuano
Journal:  Parkinsonism Relat Disord       Date:  2016-06-01       Impact factor: 4.891

4.  CAOS-Episodic Cerebellar Ataxia, Areflexia, Optic Atrophy, and Sensorineural Hearing Loss: A Third Allelic Disorder of the ATP1A3 Gene.

Authors:  Gali Heimer; Yair Sadaka; Lori Israelian; Ariel Feiglin; Alessandra Ruggieri; Christian R Marshall; Stephen W Scherer; Esther Ganelin-Cohen; Dina Marek-Yagel; Michal Tzadok; Andreea Nissenkorn; Yair Anikster; Berge A Minassian; Bruria Ben Zeev
Journal:  J Child Neurol       Date:  2015-04-20       Impact factor: 1.987

5.  Phenotypic overlap of alternating hemiplegia of childhood and CAPOS syndrome.

Authors:  Hendrik Rosewich; Dagmar Weise; Andreas Ohlenbusch; Jutta Gärtner; Knut Brockmann
Journal:  Neurology       Date:  2014-07-23       Impact factor: 9.910

Review 6.  ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia.

Authors:  Allison Brashear; Jonathan W Mink; Deborah F Hill; Niki Boggs; W Vaughn McCall; Mark A Stacy; Beverly Snively; Laney S Light; Kathleen J Sweadner; Laurie J Ozelius; Leslie Morrison
Journal:  Dev Med Child Neurol       Date:  2012-08-28       Impact factor: 5.449

7.  A novel recurrent mutation in ATP1A3 causes CAPOS syndrome.

Authors:  Michelle K Demos; Clara Dm van Karnebeek; Colin Jd Ross; Shelin Adam; Yaoqing Shen; Shing Hei Zhan; Casper Shyr; Gabriella Horvath; Mohnish Suri; Alan Fryer; Steven Jm Jones; Jan M Friedman
Journal:  Orphanet J Rare Dis       Date:  2014-01-28       Impact factor: 4.123

  7 in total
  5 in total

Review 1.  Novel pregnancy-triggered episodes of CAPOS syndrome.

Authors:  Irene J Chang; Margaret P Adam; Suman Jayadev; Thomas D Bird; Niranjana Natarajan; Ian A Glass
Journal:  Am J Med Genet A       Date:  2017-11-01       Impact factor: 2.802

Review 2.  Emerging Monogenic Complex Hyperkinetic Disorders.

Authors:  Miryam Carecchio; Niccolò E Mencacci
Journal:  Curr Neurol Neurosci Rep       Date:  2017-10-30       Impact factor: 5.081

3.  Genetically altered animal models for ATP1A3-related disorders.

Authors:  Hannah W Y Ng; Jennifer A Ogbeta; Steven J Clapcote
Journal:  Dis Model Mech       Date:  2021-10-06       Impact factor: 5.732

4.  Chinese patients with p.Arg756 mutations of ATP1A3: Clinical manifestations, treatment, and follow-up.

Authors:  Weihua Zhang; Jiuwei Li; Xiuwei Zhuo; Ji Zhou; Weixing Feng; Shuai Gong; Xiaotun Ren; Changhong Ding; Tongli Han; Fang Fang
Journal:  Pediatr Investig       Date:  2022-02-25

Review 5.  Variants of ATP1A3 in residue 756 cause a separate phenotype of relapsing encephalopathy with cerebellar ataxia (RECA)-Report of two cases and literature review.

Authors:  Mateusz Biela; Malgorzata Rydzanicz; Krystyna Szymanska; Karolina Pieniawska-Smiech; Aleksandra Lewandowicz-Uszynska; Joanna Chruszcz; Lucyna Benben; Malgorzata Kuzior-Plawiak; Pawel Szyld; Aleksandra Jakubiak; Leszek Szenborn; Rafal Ploski; Robert Smigiel
Journal:  Mol Genet Genomic Med       Date:  2021-08-02       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.